Alternative Mechanisms of MiR-34a Regulation in Cancer
Overview
General Medicine
Affiliations
MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMT or inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function.
Ullah A, Khan M, Zhang Y, Shafiq M, Ullah M, Abbas A Int J Nanomedicine. 2025; 20():25-52.
PMID: 39802382 PMC: 11717654. DOI: 10.2147/IJN.S429279.
Amer H, Kampan N, Itsiopoulos C, Flanagan K, Scott C, Kartikasari A Cancers (Basel). 2025; 16(24.
PMID: 39766086 PMC: 11674514. DOI: 10.3390/cancers16244187.
A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.
Zhao X, Qi X, Liu D, Che X, Wu G Int J Nanomedicine. 2024; 19:13461-13483.
PMID: 39713223 PMC: 11662911. DOI: 10.2147/IJN.S498729.
Ali S, Adnan Y, Ahmad Z, Chawla T, Farooqui H, Adnan Ali S BMC Cancer. 2024; 24(1):1543.
PMID: 39696052 PMC: 11657824. DOI: 10.1186/s12885-024-13259-6.
Advancements in -Based Anti-Tumor Gene Therapy Research.
Peng Y, Bai J, Li W, Su Z, Cheng X Molecules. 2024; 29(22).
PMID: 39598704 PMC: 11596491. DOI: 10.3390/molecules29225315.